/
IVVD
$0.94+$0.05 (+5.83%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$262.7M
295M shares
52-week range
$0.48 – $3.07
18% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.34%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-3.89
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $25.4M | $53.4M |
| Cost of revenue | $0 | $0 | $0 | $0 | $1.6M | $3.7M |
| Gross profit | $0 | $0 | $0 | $0 | $23.8M | $49.7M |
| Gross margin | — | — | — | — | 93.6% | 93.0% |
| R&D | $106.5M | $182.9M | $179.2M | $158.7M | $137.3M | $38.3M |
| Operating income | −$112.0M | −$226.9M | −$248.0M | −$212.8M | −$176.9M | −$55.6M |
| EBITDA | $0 | −$219.4M | −$225.8M | −$205.8M | −$166.8M | −$50.4M |
| Net income | −$112.0M | −$226.8M | −$241.3M | −$198.6M | −$169.9M | −$52.5M |
| Net margin | — | — | — | — | -669.4% | -98.2% |
| EPS (diluted) | -0.59 | -2.11 | -2.17 | -1.81 | -1.43 | -0.30 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $63M | $-0.42 | $-0.44–$-0.40 | 2 |
| 2027 | $90M | $-0.28 | $-0.32–$-0.23 | 1 |
| 2028 | $244M | $-0.10 | $-0.35–$0.14 | 2 |
| 2029 | $485M | $0.23 | $0.19–$0.27 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$12.44
Price
$0.94
Implied upside
+1218%
Peer comparison
Invivyd, Inc. Common Stock
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
www.invivyd.com- Employees
- 122
- IPO / List date
- Aug 6, 2021
- HQ
- NEW HAVEN, CT
Held by traders on TradeandTell
No one on the platform currently holds IVVD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 846,265 | $1.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IVVD yet.
